Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

October 25, 2023

Study Completion Date

October 25, 2023

Conditions
Parkinson DiseaseMultisystem AtrophyHealthy Volunteer
Interventions
DRUG

[18F]UCB-2897

"Investigational Agent:~\[18F\]UCB2897 is a clear solution formulated for intravenous (IV) injection. The product \[18F\]UCB2897is delivered in normal saline (0.9 % sodium chloride \[NaCl\]) formulated with the intent to contain approximately 3.3 % (v/v) ethanol (EtOH), polysorbate-80 (PS-80, 3.73 μL/mL) and sodium ascorbate (4.67 mg/mL). The final product bears a label with the following items: total activity (mCi), volume (mL), strength (mCi/mL), calibration date and time, batch number, and shelf life. \[18F\]UCB2897 will be stored at ambient temperature in its original container."

Trial Locations (1)

06510

Invicro, New Haven

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Invicro

OTHER

NCT05274568 - Proof of Mechanism Study to Evaluate Binding of Alfa-synuclein | Biotech Hunter | Biotech Hunter